Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Cramer, J. A.; Sapin, Christophe; François, Clément

doi:10.1111/ane.12086

Cited by 22 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Represents new line of treatment of the disease; or B. Presents improved efficacy in relation to other medication already available, based on search of evidences published in meta-analysis or direct comparison 20,21 .…”

Section: Methodsmentioning

confidence: 99%

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

et al. 2016

View full text Add to dashboard Cite

Budget Impact Analyses require a set of essential information on health technology innovation, including expected rates of adoption. There is an absence of studies investigating trends, magnitude of budgetary effects and determinants of diffusion rates for health technology innovations worldwide during the last decades. The present study proposes a pilot assessment on main determinants influencing diffusion rates of pharmaceutical innovations within the Brazilian Unified National Health System (SUS). Data from the Brazilian Health Informatics Department (DATASUS) was gathered to establish the main determinants of diffusion rates of health technology innovations in Brazil, specifically referring to pharmaceutical innovations incorporated in the Brazilian Program for Specialized Pharmaceutical Services (CEAF) at SUS. Information was retrieved on DATASUS relating to patients who had used one of the medicines incorporated into CEAF at least three years prior to the beginning of the study (2015) for treatment of each health condition available. Thus, data from patients adopting 10 different medicines were analyzed in the study. Results from the zero-one inflated beta model showed a higher influence on diffusion rates of pharmaceutical innovations due to: number of pharmaceutical competitors for treatment of the same disease available at CEAF (negative); medicine used in combination with other medication (positive); and innovative medicine within the SUS (positive). Further research on diffusion rates of health technology innovations is required, including wider scope of diseases and medications, potential confusion factors and other variables that may influence rates of adoption in different health systems.

show abstract

Section: Methodsmentioning

confidence: 99%

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A 2013 study utilizing a method for indirect comparison of antiepileptic agents used in the treatment of LGS was published in an attempt to fill this gap 31. Medications included in the analysis were clobazam, felbamate, lamotrigine, rufinamide, and topiramate.…”

Section: Efficacymentioning

confidence: 99%

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome

Faulkner¹

2015

TCRM

View full text Add to dashboard Cite

Clobazam is the newest medication approved by the US Food and Drug Administration (FDA) for the treatment of Lennox–Gastaut syndrome (LGS) in patients at least 2 years of age, although the medication has been available in countries around the world to treat epilepsy and anxiety disorders for many years. Though classified as a benzodiazepine, the drug differs structurally from other drugs in the class as it possesses nitrogen atoms at the 1 and 5 positions within the heterocyclic ring rather than at the 1 and 4 positions. This difference and the classification of clobazam as a partial agonist are believed to be responsible for the decreased incidence of sedative effects compared to other benzodiazepines. Adverse events associated with clobazam use in clinical trials have generally been mild to moderate in nature. Data from an open-label extension trial have confirmed that clobazam is efficacious for the treatment of seizures associated with LGS, particularly atonic seizures (drop seizures), over the long term. Tolerance to the drug’s antiepileptic effects does not seem to be a common occurrence. The drug has proven to be a cost-effective option for therapy, particularly due to its ability to decrease the number of seizures that require medical treatment. Clobazam represents a welcome addition to the treatment options for LGS.

show abstract

“…Existen síndromes epilépticos cuyo diagnóstico implica la refractariedad en un gran número de ocasiones, en los que la terapia combinada debería considerarse de forma muy precoz; tal es el caso del síndrome de Lennox-Gastaut y el síndrome de Dravet, entre otros. En la tabla III se especifican los FAE más eficaces y las combinaciones más apropiadas para los distintos síndromes [27,28,[31][32][33][34][35][36][37][38][39][40][41][42][43][44][45].…”

Section: Eficacia En El Tipo De Síndrome Epilépticounclassified

“…En la tabla V se reflejan algunas de las combinaciones de FAE que han sido reflejadas en la literatura científica como poseedoras de una posible sinergia, algunas con mejor rendimiento que otras [10,11,17,18,36,38,42,44,63,[65][66][67][68][69][70][71][72][73][74]. Se ha prescindido de PB y PHT, aunque existan varias referencias antiguas que recogen su utilidad en combinación, porque son FAE con numerosas interacciones y efectos adversos, actualmente de escaso uso en nuestro medio.…”

Section: Evidencia Nivelunclassified

Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015

Sánchez-Álvarez

Ramos-Lizana²,

Machado-Casas³

et al. 2015

RevNeurol

View full text Add to dashboard Cite

Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Cited by 22 publications

References 27 publications

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome

Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015

Contact Info

Product

Resources

About

Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Cited by 22 publications

References 27 publications

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox&ndash;Gastaut syndrome

Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015

Contact Info

Product

Resources

About

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome